• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

iScience . Campus-based genomic surveillance uncovers early emergence of a future dominant A(H3N2) influenza clade

tetano

Editor, Senior Moderator
iScience


. 2025 Nov 4;28(12):113941.
doi: 10.1016/j.isci.2025.113941. eCollection 2025 Dec 19. Campus-based genomic surveillance uncovers early emergence of a future dominant A(H3N2) influenza clade

Matthew Scotch[SUP] 1 2 [/SUP], Temitope O C Faleye[SUP] 1 [/SUP], Jillian M Wright[SUP] 1 [/SUP], Sarah Finnerty[SUP] 3 [/SUP], Rolf U Halden[SUP] 1 [/SUP], Arvind Varsani[SUP] 4 [/SUP]



Affiliations
Abstract

We conducted genomic surveillance during the 2022-2023 northern hemisphere influenza season at a university in the southwestern US to assess how local diversity and evolution compared to national trends. We identified 100 positive samples (19%) from clinical swabs collected at a student health clinic and observed a dominance of subtype A(H3N2) which was consistent nationally for that season. However, we found stark differences when examining H3 clades, including an early dominance of 3C.2a1b.2a.2a.3a.1 variants contrasting from country level data in which 3C.2a1b.2a.2b variants were most abundant. We found known H3 amino acid substitutions in epitope sites and estimated vaccine effectiveness to be 0.13-0.48 which aligns with national estimates for that season. Importantly, 3C.2a1b.2a.2a.3a.1 became the dominant H3 clade nationally in 2023-2024 and 2024-2025, highlighting the potential for localized genomic surveillance in semi-closed, highly dense university settings and its potential for early insight of seasonal influenza diversity.

Keywords: Immunology; Virology.

 
Back
Top Bottom